NZ703040A - Macrocyclic inhibitors of flaviviridae viruses - Google Patents

Macrocyclic inhibitors of flaviviridae viruses

Info

Publication number
NZ703040A
NZ703040A NZ703040A NZ70304013A NZ703040A NZ 703040 A NZ703040 A NZ 703040A NZ 703040 A NZ703040 A NZ 703040A NZ 70304013 A NZ70304013 A NZ 70304013A NZ 703040 A NZ703040 A NZ 703040A
Authority
NZ
New Zealand
Prior art keywords
flaviviridae viruses
macrocyclic inhibitors
compounds
macrocyclic
inhibitors
Prior art date
Application number
NZ703040A
Other languages
English (en)
Inventor
Caroline Aciro
Victoria Alexandra Steadman
Simon Neil Pettit
Karine G Poullennec
Linos Lazarides
David Kenneth Dean
Neil Andrew Dunbar
Adrian John Highton
Andrew John Keats
Dustin Scott Siegel
Kapil Kumar Karki
Adam James Schrier
Petr Jansa
Richard Mackman
Jean Yves Chiva
Original Assignee
Gilead Sciences Inc
Selcia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Selcia Ltd filed Critical Gilead Sciences Inc
Priority to NZ724503A priority Critical patent/NZ724503A/en
Publication of NZ703040A publication Critical patent/NZ703040A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ703040A 2012-06-08 2013-06-07 Macrocyclic inhibitors of flaviviridae viruses NZ703040A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ724503A NZ724503A (en) 2012-06-08 2013-06-07 Macrocyclic inhibitors of flaviviridae viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657550P 2012-06-08 2012-06-08
PCT/US2013/044826 WO2013185103A1 (en) 2012-06-08 2013-06-07 Macrocyclic inhibitors of flaviviridae viruses

Publications (1)

Publication Number Publication Date
NZ703040A true NZ703040A (en) 2016-11-25

Family

ID=48692655

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ703040A NZ703040A (en) 2012-06-08 2013-06-07 Macrocyclic inhibitors of flaviviridae viruses
NZ724503A NZ724503A (en) 2012-06-08 2013-06-07 Macrocyclic inhibitors of flaviviridae viruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ724503A NZ724503A (en) 2012-06-08 2013-06-07 Macrocyclic inhibitors of flaviviridae viruses

Country Status (20)

Country Link
US (3) US9145441B2 (cg-RX-API-DMAC10.html)
EP (1) EP2861604B1 (cg-RX-API-DMAC10.html)
JP (1) JP6209601B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150040265A (cg-RX-API-DMAC10.html)
CN (1) CN104703991B (cg-RX-API-DMAC10.html)
AU (1) AU2013270672B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014030630A2 (cg-RX-API-DMAC10.html)
CA (1) CA2875692A1 (cg-RX-API-DMAC10.html)
EA (1) EA026235B1 (cg-RX-API-DMAC10.html)
ES (1) ES2624223T3 (cg-RX-API-DMAC10.html)
HK (1) HK1211285A1 (cg-RX-API-DMAC10.html)
IL (1) IL236005A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014MN02652A (cg-RX-API-DMAC10.html)
MX (1) MX2014014766A (cg-RX-API-DMAC10.html)
NZ (2) NZ703040A (cg-RX-API-DMAC10.html)
PL (1) PL2861604T3 (cg-RX-API-DMAC10.html)
PT (1) PT2861604T (cg-RX-API-DMAC10.html)
SG (1) SG11201408047XA (cg-RX-API-DMAC10.html)
SI (1) SI2861604T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013185103A1 (cg-RX-API-DMAC10.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104703991B (zh) 2012-06-08 2018-03-23 吉利德科学公司 黄病毒科病毒的大环抑制剂
PL2859009T3 (pl) 2012-06-08 2018-03-30 Gilead Sciences, Inc. Makrocykliczne inhibitory wirusów flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MY199989A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
WO2017007892A1 (en) * 2015-07-07 2017-01-12 Nch Corporation System and method for treating water with a biological based biocide
WO2017035230A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
KR102202984B1 (ko) 2016-05-27 2021-01-13 길리애드 사이언시즈, 인코포레이티드 Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
IL265921B2 (en) 2016-10-14 2024-05-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US10961213B2 (en) 2017-01-25 2021-03-30 Basf Se Process for preparation of benzylic amides
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN109384727B (zh) * 2017-08-10 2023-07-28 中国科学院上海药物研究所 酞嗪酮类化合物、其制备方法、药物组合物及用途
CN111051305A (zh) 2017-08-22 2020-04-21 吉利德科学公司 治疗性杂环化合物
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR112020011746A2 (pt) 2017-12-13 2020-11-17 Lupin Limited compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5
KR102492115B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
BR112020016466A2 (pt) 2018-02-13 2020-12-15 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1, para tratar câncer e para aprimorar a função de células-t em pacientes com hepatite b crônica (chb), e, kit para tratar ou prevenir câncer ou uma doença ou condição.
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US20220274979A1 (en) 2018-04-18 2022-09-01 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
ES3035911T3 (en) 2018-04-19 2025-09-11 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US11098027B2 (en) 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
AU2019297428C1 (en) 2018-07-06 2023-03-23 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
CN120699039A (zh) * 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
BR112022008535A2 (pt) 2019-11-04 2022-08-09 Revolution Medicines Inc Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
PE20230779A1 (es) 2020-08-07 2023-05-09 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
CN116323623B (zh) 2020-09-18 2025-09-26 拜耳公司 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
JP2024518558A (ja) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN114634421A (zh) * 2022-02-24 2022-06-17 济宁晟泰药业有限公司 一种达沙替尼中间体的制备方法
CN120019059A (zh) 2022-07-29 2025-05-16 辉瑞公司 新型acc抑制剂
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
MX2007015909A (es) 2005-06-16 2008-03-06 Cv Therapeutics Inc Profarmacos de antagonistas del receptor de adenosina a2b.
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
EP2011786A1 (en) 2007-07-05 2009-01-07 Laboratorios del Dr. Esteve S.A. Indane-amine derivatives, their preparation and use as medicaments
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
BRPI0906946A2 (pt) 2008-01-09 2015-07-14 Univ Konkuk Ind Coop Corp Vacinas baseadas em baculovírus
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
KR101734507B1 (ko) * 2008-12-23 2017-05-11 얀센 파마슈티칼스 인코포레이티드 Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2785567C (en) 2010-01-15 2018-03-27 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
WO2011090935A1 (en) 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) * 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
PL2859009T3 (pl) 2012-06-08 2018-03-30 Gilead Sciences, Inc. Makrocykliczne inhibitory wirusów flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
BR112014029155A2 (pt) 2012-06-08 2017-06-27 Glenmark Pharmaceuticals Sa amidas de compostos de 2-amino-4-ariltiazol e respectivos sais e processos de preparação
CN104703991B (zh) 2012-06-08 2018-03-23 吉利德科学公司 黄病毒科病毒的大环抑制剂

Also Published As

Publication number Publication date
ES2624223T3 (es) 2017-07-13
USRE47334E1 (en) 2019-04-02
US20150344521A1 (en) 2015-12-03
CA2875692A1 (en) 2013-12-12
US9512175B2 (en) 2016-12-06
SG11201408047XA (en) 2015-01-29
WO2013185103A1 (en) 2013-12-12
NZ724503A (en) 2017-12-22
MX2014014766A (es) 2015-05-11
EA201492209A1 (ru) 2015-05-29
EP2861604B1 (en) 2017-03-01
CN104703991A (zh) 2015-06-10
US9145441B2 (en) 2015-09-29
PL2861604T3 (pl) 2017-08-31
SI2861604T1 (sl) 2017-05-31
CN104703991B (zh) 2018-03-23
JP2015518904A (ja) 2015-07-06
EA026235B1 (ru) 2017-03-31
HK1211285A1 (en) 2016-05-20
EP2861604A1 (en) 2015-04-22
IL236005A0 (en) 2015-02-01
BR112014030630A2 (pt) 2017-06-27
PT2861604T (pt) 2017-05-05
AU2013270672B2 (en) 2017-10-19
JP6209601B2 (ja) 2017-10-04
KR20150040265A (ko) 2015-04-14
IN2014MN02652A (cg-RX-API-DMAC10.html) 2015-08-21
HK1209730A1 (en) 2016-04-08
US20140030221A1 (en) 2014-01-30
AU2013270672A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
PH12020550552A1 (en) Inhibitors of hepatitis c virus
MX2012000959A (es) Inhibidores de los virus flaviviridae.
IN2012DN01855A (cg-RX-API-DMAC10.html)
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
HK1198387A1 (zh) 用作黃病毒科病毒抑制物之噻吩-2-羧酸衍生物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170518

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180518

LAPS Patent lapsed